Form DEFA14A MACROGENICS INC
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/8/2026
- US stock futures tumble as Trump says Iran deal is 'over', oil climbs
- Oil jumps over 4% to two-week high after Trump says deal with Iran 'over'
- Nvidia is up just 3% YTD while SOX surges 82% — what’s holding it back?
- BofA says S&P 500 technicals point to corrective Q3
- Alibaba rallies 12% after report of narrowing losses sparks pre-earnings optimism
- Morgan Stanley Reiterates Overweight Rating on Rocket Lab USA (RKLB), Bull Case Raised to $293
- Fiserv president resigns, interim leaders named for financial unit
- Nasdaq sinks as AI worries hit chipmakers
- Amazon launches bond sale seeking at least $25 billion
- Raymond James Starts SpaceX (SPCX) at Strong Buy, PT Street High $800
TD Cowen Upgrades MacroGenics (MGNX) to Buy, 'We Believe There Is Favorable Risk/Reward Heading Into The Efficacy Update By The End Of May'
April 9, 2024 5:29 AM EDTTD Cowen analyst Boris Peaker upgraded MacroGenics (NASDAQ: MGNX) from Hold to Buy.
The analyst comments "Initial Phase II safety beat expectations and increases our conviction in vobra duo ultimately conferring meaningful clinical benefit in the next update in May (PSA50 and ORR) and in H2 (rPFS). We and KOLs believe that vobra duo could at least prove better than chemo alone and be used as an important part of... More
